Dashyant Dhanak

Dashyant Dhanak

UNVERIFIED PROFILE

Are you Dashyant Dhanak?   Register this Author

Register author
Dashyant Dhanak

Dashyant Dhanak

Publications by authors named "Dashyant Dhanak"

Are you Dashyant Dhanak?   Register this Author

43Publications

1528Reads

40Profile Views

Small-Molecule Targets in Immuno-Oncology.

Cell Chem Biol 2017 Sep;24(9):1148-1160

Discovery Sciences, Janssen Research & Development, 1400 McKean Road, P O Box 776, Spring House, PA 19477, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.chembiol.2017.08.019DOI Listing
September 2017

Development and classes of epigenetic drugs for cancer.

Biochem Biophys Res Commun 2014 Dec 10;455(1-2):58-69. Epub 2014 Jul 10.

Discovery Sciences, Janssen Pharmaceuticals, 1400 McKean Road, Spring House, PA 19477, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2014.07.006DOI Listing
December 2014

Long residence time inhibition of EZH2 in activated polycomb repressive complex 2.

ACS Chem Biol 2014 Mar 31;9(3):622-9. Epub 2013 Dec 31.

Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D and ‡Platform Technology and Sciences, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/cb4008748DOI Listing
March 2014

Chromatin proteins and modifications as drug targets.

Nature 2013 Oct;502(7472):480-8

1] Biotech Research and Innovation Centre, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark. [2] Centre for Epigenetics, University of Copenhagen, Ole Maaløes Vej 5, 2200 Copenhagen, Denmark. [3] The Danish Stem Cell Center, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark.

View Article

Download full-text PDF

Source
http://www.nature.com/doifinder/10.1038/nature12751
Publisher Site
http://dx.doi.org/10.1038/nature12751DOI Listing
October 2013

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Nature 2012 Dec 10;492(7427):108-12. Epub 2012 Oct 10.

Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature11606DOI Listing
December 2012

A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force.

Cancer Res 2012 Dec 27;72(24):6319-24. Epub 2012 Nov 27.

Research Department of Cancer Biology, University College London Cancer Institute, University College London, London, United Kingdom.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-12-3658DOI Listing
December 2012

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

ACS Med Chem Lett 2012 Dec 19;3(12):1091-6. Epub 2012 Oct 19.

Cancer Epigenetics Discovery Performance Unit, Oncology Research & Development, Protein Dynamics Discovery Performance Unit, Oncology Research & Development, and Platform Technology and Sciences, GlaxoSmithKline Pharmaceuticals , Collegeville, Pennsylvania 19426, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ml3003346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025676PMC
December 2012

Cracking the code: the promise of epigenetics.

Authors:
Dashyant Dhanak

ACS Med Chem Lett 2012 Jul 14;3(7):521-3. Epub 2012 Jun 14.

Cancer Research, GlaxoSmithKline Pharmaceuticals , 1250 South Collegeville Road, Collegeville, Pennsylvania, 19460, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/ml300141hDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025814PMC
July 2012

Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides.

Bioorg Med Chem Lett 2008 Jul 10;18(14):3950-4. Epub 2008 Jun 10.

Centers of Excellence for Drug Discovery, GlaxoSmithKline, 709 Swedeland Road, King of Prussia, PA 19406, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2008.06.019DOI Listing
July 2008

Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.

Biochem J 2008 Jan;409(2):519-24

Department of Enzymology and Mechanistic Pharmacology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA.

View Article

Download full-text PDF

Source
http://biochemj.org/lookup/doi/10.1042/BJ20070681
Publisher Site
http://dx.doi.org/10.1042/BJ20070681DOI Listing
January 2008

ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism.

Nat Chem Biol 2007 Nov 7;3(11):722-6. Epub 2007 Oct 7.

Department of Enzymology and Mechanistic Pharmacology, Oncology CEDD, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nchembio.2007.34DOI Listing
November 2007

Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activity.

Bioorg Med Chem Lett 2007 Apr 19;17(7):1930-3. Epub 2007 Jan 19.

GlaxoSmithKline Pharmaceuticals, 1250 South Collegeville Road, PO Box 5089, Collegeville, PA 19426-0989, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2007.01.034DOI Listing
April 2007

Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

Peptides 2006 Nov 17;27(11):2919-26. Epub 2006 Aug 17.

Division of Cardiology, Montreal General Hospital, McGill University Health Center, Suite L3-109, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.peptides.2006.06.011DOI Listing
November 2006

Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

J Mol Cell Cardiol 2006 Aug 22;41(2):285-95. Epub 2006 Jun 22.

Division of Cardiology, Montreal General Hospital, McGill University Health Center, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yjmcc.2006.05.008DOI Listing
August 2006

3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

J Med Chem 2006 Feb;49(3):971-83

Department of Medicinal Chemistry and Drug Metabolism, the Musculoskeletal, Microbial and Proliferative Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/jm050855sDOI Listing
February 2006

A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker.

J Mol Cell Cardiol 2005 Nov 19;39(5):785-91. Epub 2005 Sep 19.

Division of Cardiology, Suite L3.109, The Montreal General Hospital, McGill University Health Center, 1650 Cedar Avenue, Montreal, Quebec, Canada H3G 1A4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yjmcc.2005.07.002DOI Listing
November 2005

ATP citrate lyase inhibition can suppress tumor cell growth.

Cancer Cell 2005 Oct;8(4):311-21

Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2005.09.008DOI Listing
October 2005

Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.

Biochemistry 2004 Dec;43(48):15258-66

Department of Enzymology and Mechanistic Pharmacology, MMPD CEDD, GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi048282tDOI Listing
December 2004

From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

Trends Pharmacol Sci 2004 Feb;25(2):76-85

Department of Vascular Biology, Cardiovascular and Urogenital Centre of Excellence for Drug Discovery, GlaxoSmithKline, PO Box 1539, 709 Swedeland Road, King of Prussia PA 19406-0939, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tips.2003.12.005DOI Listing
February 2004

Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives.

J Biol Chem 2003 May 27;278(19):16602-7. Epub 2003 Jan 27.

Department of Virology, The Metabolic and Viral Diseases Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Bloomington, Indiana 47405, USA.

View Article

Download full-text PDF

Source
http://www.jbc.org/content/278/19/16602.full.pdf
Web Search
http://www.jbc.org/cgi/doi/10.1074/jbc.M210891200
Publisher Site
http://dx.doi.org/10.1074/jbc.M210891200DOI Listing
May 2003

Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.

Br J Pharmacol 2002 Oct;137(4):449-58

Department of Vascular Biology, Cardiovascular and Urogenital Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, P.O. Box 1539 709 Swedeland Road, King of Prussia, PA 19406-0939, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.bjp.0704887DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573512PMC
October 2002